Microfluidic artificial lungs

An artificial lung brings blood close to oxygen across a thin membrane. Microfluidic versions divide blood among small channels to shorten the distance oxygen must travel. For a very premature infant, can the complete device keep exchanging gas during prolonged use, with open blood channels, little driving pressure and a manageable blood volume?[1] [3]

A microfluidic artificial lung routes blood through small channels beside oxygen, separated by a gas-permeable membrane. Can the complete neonatal device sustain gas exchange and low-pressure flow during prolonged blood contact without obstructed channels or harmful blood interactions?

The June manufacturing paper found that the blood side dominated modeled transfer resistance, so simply thinning an already thin membrane offered limited benefit. A separate June 2026 primary study used acoustically driven membrane microstreaming—small vortices that mix blood across larger channels—reporting improved oxygenation and lower platelet deposition. These are demonstrated transport and compatibility advances, not evidence that all clot-related limitations have disappeared.[1] [2]

Bench devices already meet particular neonatal oxygen-transfer targets. The remaining question is whether the complete device can sustain that performance during prolonged blood exposure without clots or harmful blood interactions. A promising exchange rate or reduced platelet coverage in one test does not establish the joint long-duration capability.[1] [2] [3]

The remaining boundary is sustained perfusion and gas transfer through the complete neonatal device under prolonged whole-blood exposure and relevant blood-property variation. Scale-up itself is already demonstrated in earlier devices. A short nominal-flow experiment or a reduction of deposited platelets supports a design direction, but does not establish long-term channel patency, clot mitigation or the behavior of all blood-contacting distributors.[1] [2] [3]

A very premature infant has little blood available to fill an external device. Low-pressure operation could also let the infant’s own circulation drive flow, reducing reliance on a separate pump. Those advantages would matter only while the device supplies oxygen without obstructing its blood channels or causing harmful blood interactions.[1] [3]

Qualification connects different scales: membrane diffusion, mixing within a channel, flow division across layers and total priming volume. The manufacturing study’s successful exchange-layer scaling leaves distributors as a major system component rather than negligible plumbing. Testing their integration with hemocompatibility and sustained gas transfer would establish the specified capability without substituting a single favorable membrane or channel measurement for the device outcome.[1] [2]